945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
Saved in:
| Published in: | Annals of oncology Vol. 29; no. suppl_8 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford University Press
01-10-2018
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Author | Coukos, G Homicsko, K Schwarzenberger, P O Kandalaft, L Disilvestro, P O'Cearbhaill, R E Macri, M Wong, P Monk, B J Bryan, J K Shohara, L O'Malley, D M Wolfer, A Sabbatini, P Rusakiewicz, S Harari, A Ricciardi, T Ryan, A Venhaus, R R |
|---|---|
| Author_xml | – sequence: 1 givenname: R E surname: O'Cearbhaill fullname: O'Cearbhaill, R E organization: Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA – sequence: 2 givenname: A surname: Wolfer fullname: Wolfer, A organization: Medical Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland – sequence: 3 givenname: P surname: Disilvestro fullname: Disilvestro, P organization: Gynecologic Oncology, Women and Infants Hospital of Rhode Island, Providence, RI, USA – sequence: 4 givenname: D M surname: O'Malley fullname: O'Malley, D M organization: Clinical Research Gynecologic Oncology, Ohio State University College of Medicine and Ohio State University, James Cancer Center, Columbus, OH, USA – sequence: 5 givenname: P surname: Sabbatini fullname: Sabbatini, P organization: Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA – sequence: 6 givenname: L surname: Shohara fullname: Shohara, L organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 7 givenname: P O surname: Schwarzenberger fullname: Schwarzenberger, P O organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 8 givenname: T surname: Ricciardi fullname: Ricciardi, T organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 9 givenname: M surname: Macri fullname: Macri, M organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 10 givenname: A surname: Ryan fullname: Ryan, A organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 11 givenname: R R surname: Venhaus fullname: Venhaus, R R organization: Clinical Research, Ludwig Cancer Research, New York, NY, USA – sequence: 12 givenname: J K surname: Bryan fullname: Bryan, J K organization: Research, Novella Clinical, Seattle, WA, USA – sequence: 13 givenname: P surname: Wong fullname: Wong, P organization: Ludwig Center for Cancer Immunotherapy, Zuckerman Research Center and Memorial Sloan Kettering Cancer Center, New York, NY, USA – sequence: 14 givenname: K surname: Homicsko fullname: Homicsko, K organization: Oncology, University Hospital and University of Lausanne, Lausanne, Switzerland – sequence: 15 givenname: L surname: Kandalaft fullname: Kandalaft, L organization: Clinical Research, University Hospital of Lausanne and Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, Switzerland – sequence: 16 givenname: S surname: Rusakiewicz fullname: Rusakiewicz, S organization: Clinical Research, University Hospital of Lausanne and Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, Switzerland – sequence: 17 givenname: A surname: Harari fullname: Harari, A organization: Clinical Research, University Hospital of Lausanne and Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, Switzerland – sequence: 18 givenname: B J surname: Monk fullname: Monk, B J organization: Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix, AZ, USA – sequence: 19 givenname: G surname: Coukos fullname: Coukos, G organization: Medical Oncology, University Hospital of Lausanne and Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne, Switzerland |
| BookMark | eNqVkMtKw0AYhQepYKo-gLt_2YBpJrfaLKUqBgSLuA9_J1Mzkrkwl2oeyPc0Wl_A1fk4nLP55mSmtOKEXGV0mdG6SFFNBUtlN-braplVxQmJsmpVJ2taZjMS0TovkpuqKM_I3Ll3SumqzuuIfNVltb0F06Pj0KRNA86HbgS9B9ZzqRMhZVDa99yiGeFD-B66YA84BIk7WPxyDKg6MPxtHNDzDgZhtNMSB-j0p7ZhJ5hQsNg-3cUwgZlWQgWZWO6E86g8WM6CtXwifUArUAFDxbidTi_Pm_iCnO5xcPzyL8_J9cP96-Yx0cG0xgqJdmwz2v6oaI8q2qOKdlJR_HP-DVxlbS8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018 |
| Copyright_xml | – notice: The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018 |
| DOI | 10.1093/annonc/mdy285.153 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19-23 October 2018, Munich, Germany |
| EISSN | 1569-8041 |
| ExternalDocumentID | 10.1093/annonc/mdy285.153 |
| GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0SF 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6J9 70D AAEDW AAJKP AAJQQ AAKUH AALRI AAMVS AAOGV AAPNW AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABVKL ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVLN ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFETI AFIYH AFOFC AFXEN AGINJ AGKEF AGSYK AHMBA AHXPO AIAGR AIJHB AITUG ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AXUDD BAWUL BAYMD BHONS BTRTY BVRKM CDBKE CKLRP COF CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EJD F9B FDB GJXCC GX1 H13 H5~ HAR HW0 HZ~ I09 IH2 IOX J21 KAQDR KOM KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NCXOZ NGC NOYVH NU- O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RW1 RXO TCURE TEORI TJX TR2 W8F WOQ X7H YAYTL YFH YKOAZ ZKX ~91 |
| ID | FETCH-oup_primary_10_1093_annonc_mdy285_1533 |
| ISSN | 0923-7534 |
| IngestDate | Wed Sep 11 04:52:36 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | suppl_8 |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-oup_primary_10_1093_annonc_mdy285_1533 |
| ParticipantIDs | oup_primary_10_1093_annonc_mdy285_153 |
| PublicationCentury | 2000 |
| PublicationDate | 20181001 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: 20181001 day: 01 |
| PublicationDecade | 2010 |
| PublicationTitle | Annals of oncology |
| PublicationYear | 2018 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| SSID | ssj0006929 |
| Score | 4.6296535 |
| SourceID | oup |
| SourceType | Publisher |
| Title | 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC) |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swEBdpB2MvY5_sm3vYoCHz0thOIj-WNqNm6xa6wvZmLNtZA7EVnHgsf9D-z93pFNtbS8ke9mIUIR-x7od0d7r7SYjXyWwwlIfB2BkEw8TxcY91lEyVk478Q6lUihYHxSFPv4w_fZMnE3_S6Wy5_5q-_6pp7ENdU-XsP2i7Food2Ead4xO1js-d9B74w-lRb3mJu1MvRDFhyBSyJn_8Msu1M6eSEFt4teFAbFqVxPqdx4osTvOLwgWGRCD7vlnEZJcu5ku90jmd6uifuqwUHcrT-OnHExpN-eiUWVdUuYNOPBmmxbpXUkDfUEDpH-iX43KSENBK8-L55-NtKOIKobMukj9C_iYtB7VFN2jzWcl5U0bxVS9m9l7u2jSfr-YLIhHhSp5pW84Z3SDD-QM2HGwDHwNZp9CtbyqobEc4Xc9Bb4zjFZld30eBQ5RL7Q3AficDfUWXqUby2t2FmbfiosAZwEaeblw5fDdgtuO_aLtvHL8nbrm4MJoQQPihthxGgcvckPaPb0_hA6_PQvqNCC7IbNlCF_fEXevEwBGj777oZMUDcfvMpmk8FL8MCMGAEMJ-GIKBIOgZXANBIAhCA0E4MO0uIPyghh_U8IMW_OAAwdcFbFyFHtTQAws9YOjhSwi87iPx9v3k4vjUwS-Mlsy6EnG2hBfxTEQ8ExG5K4_FPnZlTwSMXc_zsyCW5NV4SRorT_luii59rGaxHD0Vb3YS-WzHcc_FnQaZL8T-uqyyl2JvlVavjGZ_AzjDmzk |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=945PA+phase+I%2FII+study+of+chemo-immunotherapy+with+durvalumab+%28durva%29+and+pegylated+liposomal+doxorubicin+%28PLD%29+in+platinum-resistant+recurrent+ovarian+cancer+%28PROC%29&rft.jtitle=Annals+of+oncology&rft.au=O%27Cearbhaill%2C+R+E&rft.au=Wolfer%2C+A&rft.au=Disilvestro%2C+P&rft.au=O%27Malley%2C+D+M&rft.date=2018-10-01&rft.pub=Oxford+University+Press&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=29&rft.issue=suppl_8&rft_id=info:doi/10.1093%2Fannonc%2Fmdy285.153&rft.externalDocID=10.1093%2Fannonc%2Fmdy285.153 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon |